|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Carteolol#Adverse Reactions]] |
| {{Carteolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| The following adverse reactions have been reported in clinical trials with Ocupress Ophthalmic Solution:
| |
| | |
| ===Ocular===
| |
| | |
| Transient eye irritation, burning, tearing, conjunctival hyperemia and edema occurred in about 1 of 4 patients. Ocular symptoms including blurred and cloudy vision, photophobia, decreased night vision, and ptosis and ocular signs including blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally.
| |
| | |
| ===Systemic===
| |
| | |
| As is characteristic of nonselective adrenergic blocking agents, Ocupress may cause bradycardia and decreased blood pressure (see WARNINGS). The following systemic events have occasionally been reported with the use of Ocupress: cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, and taste perversion.
| |
| | |
| The following additional adverse reactions have been reported with ophthalmic use of beta1 and beta2 (nonselective) adrenergic receptor blocking agents:
| |
| | |
| '''Body As a Whole''': [[Headache]]
| |
| | |
| '''Cardiovascular''': [[Arrhythmia]], [[syncope]], [[heart block]], cerebral vascular accident, [[cerebral ischemia]], [[congestive heart failure]], [[palpitation]] (see WARNINGS).
| |
| | |
| '''Digestive''': [[Nausea]]
| |
| | |
| '''Psychiatric''': [[Depression]]
| |
| | |
| '''Skin''': [[Hypersensitivity]], including localized and generalized rash
| |
| | |
| '''Respiratory''': [[Bronchospasm]] (predominantly in patients with pre-existing bronchospastic disease), [[respiratory failure]] (see WARNINGS)
| |
| | |
| '''Endocrine''': Masked symptoms of [[hypoglycemia]] in insulin-dependent diabetics (see WARNINGS)
| |
| | |
| '''Special Senses''': Signs and symptoms of [[keratitis]], [[blepharoptosis]], [[visual disturbance]]s including refractive changes (due to withdrawal of miotic therapy in some cases), [[diplopia]], [[ptosis]].
| |
| | |
| Other reactions associated with the oral use of nonselective adrenergic receptor blocking agents should be considered potential effects with ophthalmic use of these agents.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZEBETA (BISOPROLOL FUMARATE) TABLET [DURAMED PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85 | publisher = | date = | accessdate = 4 February 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |